10-Q/A

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-Q/A
                                (Amendment No. 1)

Mark One
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

    For the quarterly period ended March 31, 2012

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

    For the transition period from ____________ to _____________

                         Commission File No. 333-168930


                                 VANTAGE HEALTH
                 (Name of small business issuer in its charter)

                                     Nevada
         (State or other jurisdiction of incorporation or organization)

                             C/O Steven T Lowe Esq.
                                    Suite 640
                          11400 West Olympic Boulevard
                       Los Angeles, California 90064-1567
                    (Address of principal executive offices)

                                 (310) 477-5811
                          (Issuer's telephone number)

Securities registered pursuant to                          Name of each exchange
     Section 12(b) of the Act:                              on which registered:
                                      None

          Securities registered pursuant to Section 12(g) of the Act:
                              Common Stock, $0.001
                                (Title of Class)

Indicate by checkmark whether the issuer: (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. Yes [X] No[ ]

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). YES [X] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filed, an
accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by checkmark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the
Preceding Five Years. N/A

Indicate by checkmark whether the issuer has filed all documents and reports
required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act
of 1934 after the distribution of securities under a plan confirmed by a court.
Yes[ ] No[ ]

Applicable Only to Corporate Registrants

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the most practicable date:

     Class                                        Outstanding as of May 15, 2012
     -----                                        ------------------------------
Common Stock, $0.01                                         80,025,000

                                EXPLANATORY NOTE

The purpose of this Amendment No. 1 to the Company's Quarterly Report on Form
10-Q for the quarterly period ended March 31, 2012, filed with the Securities
and Exchange Commission on May 21, 2012 (the "Form 10-Q"), is solely to furnish
Exhibit 101 to the Form 10-Q. Exhibit 101 provides the financial statements and
related notes from the Form 10-Q formatted in XBRL (Extensible Business
Reporting Language).

No other changes have been made to the Form 10-Q. This Amendment No. 1 to the
Form 10-Q continues to speak as of the original filing date of the Form 10-Q,
does not reflect events that may have occurred subsequent to the original filing
date, and does not modify or update in any way disclosures made in the original
Form 10-Q.

Pursuant to rule 406T of Regulation S-T, the Interactive Data Files on Exhibit
101 hereto are deemed not filed or part of a registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as
amended, are deemed not filed for purposes of Section 18 of the Securities Act
of 1934, as amended, and otherwise are not subject to liability under those
sections.

ITEM 6. EXHIBITS

31.1*    Certification of Chief Executive Officer pursuant to Securities
         Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

31.2*    Certification of Chief Financial Officer pursuant to Securities
         Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

32.1*    Certifications pursuant to Securities Exchange Act of 1934 Rule
         13a-14(b) or 15d- 14(b) and 18 U.S.C. Section 1350, as adopted pursuant
         to Section 906 of the Sarbanes- Oxley Act of 2002.

101      Interactive Data Files pursuant to Rule 405 of Regulation S-T.

----------
* Filed previously

                                       2

                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                  VANTAGE HEALTH


Dated: May 23, 2012               By: /s/ Lisa Ramakrishnan
                                      ------------------------------------------
                                      Lisa Ramakrishnan, President and
                                      Chief Executive Officer


Dated: May 23, 2012               By: /s/ Lisa Ramakrishnan
                                      ------------------------------------------
                                      Lisa Ramakrishnan, Chief Financial Officer


                                        3

XML

PROPERTY AND EQUIPMENT	9 Months Ended
	Mar. 31, 2012
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	NOTE 2 - PROPERTY AND EQUIPMENT   Major classes of property and equipment consist of the following:                                               March 31, 2012        June 30, 2011                                             --------------        ------------- Construction in process                       $ 16,295               $      0 Vehicles                                        11,050                      0 Furniture and fixtures                           2,301                      0                                               --------               --------                                                 29,646                      0 Less accumulated depreciation                     (368)                     0                                               --------               --------                                               $ 29,278               $      0                                               ========               ========   During 2012 and 2011, the Company recorded no provisions for the impairment of assets.

XML

SUMMARY OF ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2012
SUMMARY OF ACCOUNTING POLICIES
SUMMARY OF ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF ACCOUNTING POLICIES   Nature of Business Vantage Health ("Vantage Health" and the "Company") is a development stage company and was incorporated in Nevada on April 21, 2010.   The Company intends to build and operate an Active Pharmaceutical Ingredients ("APIs") manufacturing plant alongside a formulation and packaging plant in South Africa to meet the growing market needs for Anti-retrovirals ("ARVs") in South Africa and potentially other African countries. The company intends to build an Antiretroviral Active Pharmaceutical Ingredient (API) manufacturing plant in South Africa in order to supply the growing demand in the fight against HIV/AIDS.   Development Stage Company The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles related to development-stage companies. A development-stage company is one in which planned principal operations have not commenced or if its operations have commenced, and there has been no significant revenues there from.   Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission ("SEC"), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's Form S-1/A filed with the SEC as of and for the period ended June 30, 2011. In the opinion of management, all adjustments necessary in order for the financial statements to be not misleading have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results expected for the full year. The Company has adopted a June 30 year end.   Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.   Cash and Cash Equivalents Vantage Health considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2012 and June 30, 2011, the Company had $368,126 and $14,223 of cash, respectively.   Property and Equipment Property and equipment are recorded at cost and are depreciated, when placed in service, using principally the straight-line method over the estimated useful lives of the related assets. Estimated useful lives generally range from two to seven years for furniture, equipment and automobiles. Leasehold improvements are amortized over the estimated useful lives of the related assets or leases, whichever is shorter.   Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.   Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.   Revenue Recognition The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured.   Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company's net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of March 31, 2012.   Other Comprehensive Income (Loss) Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholder's equity that, under GAAP, are excluded from net income (loss), including foreign currency translation adjustments, gains and losses related to certain derivative contracts, and gains or losses, prior service costs or credits, and transition assets or obligations associated with pension or other postretirement benefits that have not been recognized as components of net periodic benefit cost.   Foreign Currency Translation The functional currency of the Company is the United States Dollar. The financial statements of the Company's South African subsidiary are translated from the South African Rand to U.S. dollars using the period exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. The financial statements of the Company's Tanzania subsidiary are translated from the Tanzanian Shilling to U.S. dollars using the period exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transaction occurs. Net gains and losses resulting from foreign exchange translations are included in the statements of operations and changes in stockholders' equity as other comprehensive income (loss).   Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with SFAS No. 123 and 123 (R) (ASC 718). To date, the Company has not adopted a stock option plan and has not granted any stock options.   Recent Accounting Pronouncements The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow.

XML

CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Mar. 31, 2012	Jun. 30, 2011
Current Assets
Cash and equivalents	$ 368,126	$ 14,223
Accounts receivable	33,957	0
Total Current Assets	402,083	14,223
Property and equipment, net	29,278	0
Note receivable	1,386	0
Note receivable - related party	2,205	0
TOTAL ASSETS	434,952	14,223
Current Liabilities
Accounts payable and accrued expenses	57,579	47,815
Long - Term Liabilities
Shareholder loans	852,539	328,322
Total Liabilities	910,118	376,137
Stockholders' Deficit
Common Stock, $.001 par value, 250,000,000 shares authorized, 80,025,000 and 74,250,000 shares issued and outstanding, respectively	80,025	74,250
Additional paid-in capital	380,435	97,460
Stock subscription receivable	(118,750)	0
Non-controlling interest	(285,032)	(142,238)
Accumulated other comprehensive income (loss)	30,816	(10,485)
Deficit accumulated during the development stage	(562,660)	(380,901)
Total Stockholders' Deficit	(475,166)	(361,914)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 434,952	$ 14,223

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Common Stock Shares	Common Stock Amount USD ($)	Additional Paid In Capital USD ($)	Stock Subscription Receivable USD ($)	Non-Controlling Interest USD ($)	Accumulated Other Comprehensive Income (Loss) USD ($)	Deficit Accumulated During the Development Stage USD ($)	Total. USD ($)
Balance at Apr. 21, 2010	0	0	0	0	0	0	0	0
Shares issued to founder for cash	60,000,000	60,000	0	0	0	0	0	60,000
Shares issued for cash at $0.0015 per share	3,712,500	3,713	1,856	0	0	0	0	5,569
Shares issued for cash at $0.002 per share	5,000,000	5,000	5,000	0	0	0	0	10,000
Shares issued for cash at $0.0025 per share	3,700,000	3,700	5,550	0	0	0	0	9,250
Shares issued for cash at $0.00275 per share	1,287,500	1,287	2,254	0	0	0	0	3,541
Shares issued for cash at $0.003 per share	450,000	450	900	0	0	0	0	1,350
Deemed dividend created by acquisition of 51% of entity under common control		$ 0	$ 0	$ 0	$ 0	$ 0	$ (85,200)	$ (85,200)
Net loss for the year ended June 30, 2010		0	0	0	(637)	6,010	(6,627)	(1,254)
Balance at Jun. 30, 2010	74,150,000	74,150	15,560	0	(637)	6,010	(91,827)	3,256
Debt forgiven shareholder		0	50,000	0	0	0	0	50,000
Shares issued for services	100,000	100	31,900	0	0	0	0	32,000
Net loss for the year ended June 30, 2011		0	0	0	(141,601)	(16,495)	(289,074)	(447,170)
Balance at Jun. 30, 2011	74,250,000	74,250	97,460	0	(142,238)	(10,485)	(380,901)	(361,914)
Warrants exercised for cash or notes at $0.05 per share	5,775,000	5,775	282,975	(118,750)	0	0	0	170,000
Acquisition of 51% of entity		0	0	0	2,206	0	0	2,206
Net loss for the nine months ended March 31, 2012		$ 0	$ 0	$ 0	$ (145,000)	$ 41,301	$ (181,759)	$ (285,458)
Balance at Mar. 31, 2012	80,025,000	80,025	380,435	(118,750)	(285,032)	30,816	(562,660)	(475,166)

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended		23 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (181,759)	$ (156,618)	$ (445,460)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Deposit impairment.	0	0	50,000
Depreciation	364	0	364
Loss attributable to non-controlling interest	(145,000)	(117,028)	(287,238)
Changes in assets and liabilities:
(Increase) decrease in accounts receivable	(33,957)	0	(33,957)
(Increase) decrease in prepaid expenses	0	23,349	0
Increase (decrease) in accounts payable and accrued expenses	9,764	1,454	57,579
Net Cash Used by Operating Activities	(350,588)	(248,843)	(658,712)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of furniture and fixtures	(29,642)	0	(29,642)
Cash paid for deposit	0	(50,000)	(50,000)
Notes receivable extended	(3,591)	0	(3,591)
Cash paid for acquisition of 51% interest in Moxisign	0	0	(3,643)
Net Cash Used by Investing Activities	(33,233)	(50,000)	(86,876)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sales of common stock	0	0	89,710
Non-controlling interest in Vantage Health Tanzania	2,206	0	2,206
Proceeds from exercise of stock warrants	170,000	0	170,000
Proceeds from notes payable - related parties	524,217	213,827	824,482
Payments on notes payable - related parties	0	0	(3,500)
Net Cash Provided by (Used by) Financing Activities	696,423	213,827	1,082,898
Effect of exchange rate changes on cash	41,301	(17,833)	30,816
NET INCREASE (DECREASE) IN CASH	353,903	(102,849)	368,126
Cash, beginning of period	14,223	121,034
Cash, end of period	368,126	18,185	368,126
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	0	0	0
Cash paid for income taxes	0	0	0
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Deemed dividend related to acquisition of subsidiary	0	0	85,200
Exercise of stock warrants for stock subscription receivable	$ 268,750	$ 0	$ 268,750

XML

CONSOLIDATED BALANCE SHEETS PARENTHETICALS (unaudited) (USD $)	Mar. 31, 2012	Jun. 30, 2011
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	250,000,000	250,000,000
Common Stock, shares issued	80,025,000	74,250,000
Common Stock, shares outstanding	80,025,000	74,250,000

XML

SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2012
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 10 - SUBSEQUENT EVENTS   On April 14, 2012, Dr. Lisa Ramakrishnan reclaimed her role as CEO following the mutually agreed upon termination of Mr. John Harris, the previous CEO.   On October 24, 2011, Vantage Health Tanzania Ltd was awarded and subsequently accepted a contract from the University of Dar es Salaam to supply medical supplies and goods with a total contract value of $850,000. This contract is to be carried out over a period beginning November 1, 2011 and ending September 30, 2012. Vantage Health Tanzania Ltd has already begun fulfilling this contract and is recognizing revenues from this contract.   Vantage Health's South African subsidiary, Moxisign (Pty) Ltd., is in the final stages of entering into a 5 year contract with a health and beauty focused retail and supply group with over 590 stores across southern Africa. This contact is expected to generate approximately $10,000,000 in gross revenue for that entity. This contract is not yet finalized.   Management has evaluated subsequent events through the date on which the financial statements were issued, and has determined it does not have any material subsequent events to disclose other than those mentioned above.

XML

Document and Entity Information	9 Months Ended
	Mar. 31, 2012	May 15, 2012
Document and Entity Information
Entity Registrant Name	Vantage Health
Document Type	10-Q
Document Period End Date	Mar. 31, 2012
Amendment Flag	false
Entity Central Index Key	0001497130
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		80,025,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		9 Months Ended		23 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
REVENUES	$ 32,397	$ 0	$ 68,772	$ 0	$ 68,772
COST OF GOODS SOLD
Medical goods	36,524	0	72,176	0	72,176
GROSS PROFIT (LOSS)	(4,127)	0	(3,404)	0	(3,404)
OPERATING EXPENSES
Professional fees	6,495	5,065	17,216	18,386	51,607
Office expenses	54,535	6,444	175,414	9,920	203,548
Officer/director compensation	0	0	3,500	0	10,500
Stock based compensation	0	0	0	0	32,000
Consulting	22,089	64,483	49,101	200,088	262,072
Deposit impairment	0	0	0	0	50,000
Travel and entertainment	8,785	18,894	76,801	44,221	148,259
Bank fees	191	300	1,323	1,099	3,379
TOTAL OPERATING EXPENSES	92,095	95,186	323,355	273,714	761,365
LOSS FROM OPERATIONS	(96,222)	(95,186)	(326,759)	(273,714)	(764,769)
OTHER INCOME (EXPENSE)
Interest income	0	0	0	68	69
TOTAL OTHER INCOME (EXPENSE)	0	0	0	68	69
LOSS BEFORE NON-CONTROLLING INTEREST	(96,222)	(95,186)	(326,759)	(273,646)	(764,700)
LESS: LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST	40,973	41,817	145,000	117,028	287,238
LOSS BEFORE PROVISION FOR INCOME TAXES	(55,249)	(53,369)	(181,759)	(156,618)	(477,462)
PROVISION FOR INCOME TAXES	0	0	0	0	0
NET LOSS	$ (55,249)	$ (53,369)	$ (181,759)	$ (156,618)	$ (477,462)
LOSS PER SHARE: BASIC AND DILUTED	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED AVERAGE COMMON SHARES OUTSANDING:
BASIC AND DILUTED	80,025,000	74,150,000	78,859,149	74,150,000

XML

STOCK WARRANTS	9 Months Ended
	Mar. 31, 2012
STOCK WARRANTS
STOCK WARRANTS	NOTE 5 - STOCK WARRANTS   The Company issued 7,859,375 stock warrants in connection with the issuance of common stock. The Company has accounted for these warrants as equity instruments in accordance with EITF 00-19 (ASC 815-40), Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, and as such, will be classified in stockholders' equity as they meet the definition of "...indexed to the issuer's stock" in EITF 01-06 (ASC 815-40) The Meaning of Indexed to a Company's Own Stock. The Company has estimated the fair value of the warrants issued in connection with the private placement at $13 as of the grant dates using the Black-Scholes option pricing model. Each common stock purchase warrant has an exercise price of $3.00 and will expire 36 months from the effective date of the S-1. The Company has the right to call the common stock purchase warrants within ten days written notice if the Company's common stock is trading at or above $3.00 per share and has average daily trading volume of 200,000 shares of twenty consecutive days. No adjustment was made to the financial statements due to materiality.   On August 4, 2011 the exercise price for all the outstanding warrants was revised from $3.00 to $0.05 per share. The warrants were revalued on that date at $1,611,135. The stock and warrants were originally sold for total value of $13,541. As the value of the warrants cannot exceed the total value of the equity sale, no further adjustments are necessary.   During the quarter ended September 30, 2011 warrants were exercised for 5,775,000 common shares of stock, for $20,000 in cash and notes receivable totaling $268,750. There are 2,084,375 stock warrants remaining as of September 30, 2011.   Key assumptions used by the Company are summarized as follows at the original grant date and the date of revision:                                                August 4, 2011       June 30, 2010                                              --------------       ------------- Stock price                                       $0.25              $0.00275 Exercise price                                    $0.05              $   3.00 Expected volatility                                  86%                  105% Expected dividend yield                            0.00%                 0.00% Risk-free rate over the estimated expected life of the warrants                     0.27%                 0.84% Expected term (in years)                           1.92                     3

XML

COMMON STOCK	9 Months Ended
	Mar. 31, 2012
COMMON STOCK
COMMON STOCK	NOTE 4 - COMMON STOCK   The Company has 250,000,000 shares of $0.001 par value common stock.   During the period ended June 30, 2010 the Company issued 74,150,000 shares of common stock ranging from $0.001 to $0.003 per share. Vantage received total proceeds of $89,710.   During the year ended June 30, 2011, a shareholder forgave loans totaling $50,000 which have been recorded as contributed capital.   On June 30, 2011 a director of the company was issued 100,000 shares of restricted common stock valued at $32,000 for services rendered.   During the quarter ended September 30, 2011 warrants were exercised for 5,775,000 common shares of stock, for $20,000 in cash and notes receivable totaling $268,750.   During the quarter ended March 31, 2012 subscriptions receivable were collected in the amount of $150,000.   There are 80,025,000 shares issued and outstanding as of March 31, 2012.

XML

LIQUIDITY AND GOING CONCERN	9 Months Ended
	Mar. 31, 2012
LIQUIDITY AND GOING CONCERN
LIQUIDITY AND GOING CONCERN	NOTE 8 - LIQUIDITY AND GOING CONCERN   The Company has limited working capital, has incurred losses since inception, and has not yet received material revenues from sales of products or services. These factors create substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.   The ability of Vantage Health to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management's plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

XML

NON-CONTROLLING INTEREST	9 Months Ended
	Mar. 31, 2012
NON-CONTROLLING INTEREST
NON-CONTROLLING INTEREST	NOTE 6 - NON-CONTROLLING INTEREST   On June 14, 2010, Vantage acquired 51% of an entity under common control for cash totaling $3,643. For purposes of these financial statements, the subsidiary has been consolidated via the acquisition method. We have recorded a deemed dividend of $85,200 since the book value of Moxisign's liabilities exceeded the book value of its assets. The assets and liabilities of Moxisign have been recorded at amounts equal to the carrying value on Moxisign's books as per ASC 805-020. At the acquisition date, Moxisign had current assets of $27,751, current liabilities of $1,928 and long-term liabilities of $102,669.   On June 1, 2011, Vantage acquired 51% of a newly established entity for a note totaling $2,295. For purposes of these financial statements, the subsidiary has been consolidated via the acquisition method. The assets and liabilities of Vantage Tanzania Limited have been recorded at amounts equal to the carrying value on Vantage Tanzania Limited's books as per ASC 805-020. At the acquisition date, Vantage Tanzania Limited had current assets of $0, current liabilities of $0 and long-term liabilities of $0.

XML

COMMITMENTS	9 Months Ended
	Mar. 31, 2012
COMMITMENTS
COMMITMENTS	NOTE 7 - COMMITMENTS   Vantage Health neither owns nor leases any real or personal property. An officer has provided office services without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

XML

INCOME TAXES	9 Months Ended
	Mar. 31, 2012
INCOME TAXES
INCOME TAXES	NOTE 9 - INCOME TAXES   For the nine months ended March 31, 2012, Vantage Health has incurred a net loss before minority interest of approximately $314,364 and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. The cumulative net operating loss carry-forward is approximately $471,000 at March 31, 2012, and will expire beginning in the year 2030. The provision for Federal income tax consists of the following for the three months ended March 31, 2012 and 2011:                                                  March 31, 2012     March 31, 2011                                                --------------     -------------- Federal income tax benefit attributable to:   Current operations                              $ 18,785           $ 19,799   Less: valuation allowance                        (18,785)           (19,799)                                                   --------           -------- Net provision for Federal income taxes            $      0           $      0                                                   ========           ========   The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows:                                                  March 31, 2012      June 30, 2011                                                --------------      ------------- Deferred tax asset attributable to:   Net operating loss carryover                    $ 160,140          $  89,651   Valuation allowance                              (160,140)           (89,651)                                                   ---------          --------- Net deferred tax asset                            $       0          $       0                                                   =========          =========

XML

CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS) (unaudited) (USD $)	3 Months Ended		9 Months Ended		23 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Net Loss	$ (55,249)	$ (53,369)	$ (181,759)	$ (156,618)	$ (477,462)
Foreign Currency Translation:
Change in cumulative translation adjustment	(20,601)	5,608	41,301	(17,431)	30,816
Income tax benefit (expense)	0	0	0	0	0
Total	$ (20,601)	$ 5,608	$ 41,301	$ (17,431)	$ 30,816

XML

SHAREHOLDER LOANS	9 Months Ended
	Mar. 31, 2012
SHAREHOLDER LOANS
SHAREHOLDER LOANS	NOTE 3 - SHAREHOLDER LOANS   During the period ended June 30, 2010 the company received loans from two shareholders for $100,699, $30,000 and $3,500. The loans are non-interest bearing, unsecured and are due on July 13, 2013.   During the year ended June 30, 2011, the $3,500 loan was repaid in full.   An additional $247,623 was loaned from a shareholder during the year ended June 30, 2011.   During the year ended June 30, 2011, a shareholder forgave loans totaling $50,000 which have been recorded as contributed capital.   The total amount due to the shareholders was $852,539 and $328,322 as of March 31, 2012 and June 30, 2011, respectively.